Media Mention

Morgan Xu Comments on Proposed U.S. Investment Restrictions Affecting China Biotech Deals

November 20, 2026

Partner Morgan Xu was featured in a South China Morning Post article examining how new rules proposed by the U.S. Treasury Department on outbound investment restrictions could impact dealmaking between U.S. pharmaceutical companies and Chinese biotech firms.

“Washington wants to restrict certain investments that could strengthen China’s technological capabilities; Beijing wants to retain control over certain foundational Chinese technologies,” Xu said.

Read the full article in the South China Morning Post.

Key Contacts